International Journal of Pharmaceutical and Phytopharmacological Research
ISSN (Print): 2250-1029
ISSN (Online): 2249-6084
Publish with eIJPPR Submission
2026   Volume 16   Issue 2

Multimodal Molecular Intelligence for Natural Product Drug Discovery: Integrating Chemical Structures, Bioassays, Omics Profiles, Text Evidence, and Clinical Signals
Download PDF


, ,
  1. Department of AI for Respiratory and Anti-asthmatic Herbal Formulations, Faculty of Pharmacy, University of Nottingham, Nottingham, United Kingdom
  2. Department of Computational Pharmacology for Histamine Receptors, Faculty of Pharmacy, University of Southampton, Southampton, United Kingdom.
Citation
Vancouver
Bennett O, Collins H, Foster J. Multimodal Molecular Intelligence for Natural Product Drug Discovery: Integrating Chemical Structures, Bioassays, Omics Profiles, Text Evidence, and Clinical Signals. Int J Pharm Phytopharmacol Res. 2026;16(2):85-105. https://doi.org/10.51847/CFx9mQDN3R
APA
Bennett, O., Collins, H., & Foster, J. (2026). Multimodal Molecular Intelligence for Natural Product Drug Discovery: Integrating Chemical Structures, Bioassays, Omics Profiles, Text Evidence, and Clinical Signals. International Journal of Pharmaceutical And Phytopharmacological Research, 16(2), 85-105. https://doi.org/10.51847/CFx9mQDN3R
Download citation:   EndNote   RIS
Article Link:
Downloads: 30
Views: 73
Abstract

Natural product drug discovery increasingly draws on heterogeneous evidence spanning chemical structures, biological assays, molecular profiles, published literature, and clinical observations, yet these evidence streams are commonly stored, modelled, and interpreted in isolation. This article proposes a multimodal molecular intelligence framework for organizing and integrating such evidence without treating computational convergence as proof of mechanism, efficacy, safety, or clinical utility. The framework begins with traceable natural product identity and botanical-source records, followed by complementary representations of chemical structures, stereochemistry, molecular descriptors, fingerprints, and molecular graphs. Bioassay evidence is incorporated with assay metadata, exposure context, target annotations, and explicit confidence boundaries. Transcriptomic, proteomic, metabolomic, genomic, microbiomic, pathway, and network evidence are positioned as context-dependent sources of mechanistic hypotheses. Literature mining, named entity recognition, relation extraction, knowledge graphs, and citation traceability provide structured text evidence while preserving source provenance. Clinical literature, real-world observations, pharmacovigilance reports, adverse-event information, ADMET evidence, and toxicity signals contribute translational and safety context but are not treated as causal confirmation. The proposed architecture combines modality alignment, cross-modal consistency assessment, conflict detection, missing-data handling, uncertainty estimation, bias assessment, expert review, candidate-prioritization boundaries, validation planning, and iterative feedback. Its principal contribution is a provenance-preserving and validation-gated framework that supports research prioritization while maintaining explicit no-clinical-claim boundaries.

Related articles:
Most viewed articles:
Naproxen in Pain and Inflammation – A Review
Vol 11 Issue 1, 2021 | Svetoslav Nikolaev Stoev
An Overview on Emulgel
Vol 9 Issue 1, 2019 | Sreevidya V.S
Volume 16
Issue 4
2026

Call for Papers
[email protected]
Issues
Associations
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2026 International Journal of Pharmaceutical and Phytopharmacological Research
Authors retain copyright of their article if they are accepted for publication.